Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
Open accessAbstract
Responses of Seropositive Persons to a Single SARS-CoV-2 Vaccine Some persons who have recovered from Covid-19 have antibodies to the spike protein of SARS-CoV-2. In 43 such persons who had receive...
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
A single dose of vaccine boosts cross-neutralizing antibody responses to the Delta variant.
“Therefore, as shown with other variants 23,24 , a single dose of vaccine boosts cross-neutralizing antibody responses to the Delta variant.”
From Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization (2021) · cites this paper as [24]
In the main text (page not specified), the paper reports that one mRNA vaccine dose rapidly increased spike IgG antibody titers in seropositive participants. It does not report neutralization measurements or responses to other variants. The citation accompanies “as shown with other variants”; the Delta-specific conclusion is the citing authors’ own. (LLM, conf=0.86)
Experimental — accuracy not yet measuredIn people with prior infection, a single vaccine dose triggers swift, strong recall of humoral immunity, and neutralizing activity usually surpasses that seen after two doses in infection-naive people.
“the vaccination of previously infected individuals drives a rapid and very potent recall of humoral immunity, even after a single vaccine dose70–72, with serological neutralizing activity generally exceeding levels seen after two vaccine doses in naive participants.”
From Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection (2021) · cites this paper as [70]
Vaccination increased plasma RBD antibody levels in convalescent individuals, with IgG titres increasing by nearly 30-fold compared with unvaccinated individuals.
“Consistent with previous reports5–8, vaccination increased the plasma RBD antibody levels, with IgG titres increasing by nearly 30-fold compared with unvaccinated individuals (Fig. 1a, right).”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [7]
Vaccination boosts the neutralizing response by 1.5 orders of magnitude by inducing additional plasma cell differentiation from the memory B cell compartment.
“Vaccination boosts the neutralizing response by 1.5 orders of magnitude by inducing additional plasma cell differentiation from the memory B cell compartment5,7,35.”
From Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection (2021) · cites this paper as [7]
Prior work reports that vaccination generates memory B cells and antibodies that neutralize SARS-CoV-2, including variants like B.1.351.
“Recent studies have documented strong memory B cell and antibody responses post-vaccination that neutralize SARS-CoV-2, including variants of concern (VOCs) such as B.1.351 (Beta) (Goel et al., 2021; Krammer et al., 2021; Sahin et al., 2020; Widge et al., 2021).”
From Rapid induction of antigen-specific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination (2021) · cites this paper as Krammer et al., 2021
Beta and Delta are relatively poorly neutralized by convalescent sera obtained from unvaccinated individuals infected with non-VOC virus.
“In addition, Beta and Delta are relatively poorly neutralized by convalescent sera obtained from unvaccinated individuals infected with non-VOC virus ( 7 – 9 , 21 ).”
From Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa (2021) · cites this paper as [21]
Both the Beta and Delta variants are associated with decreased neutralization by some anti-RBD and anti-NTD monoclonal antibodies, though each remains responsive to at least one anti-RBD.
“Both the Beta and Delta variants are associated with decreased neutralization by some anti-receptor binding-domain (anti-RBD) and anti-N-terminal domain (anti-NTD) monoclonal antibodies though both Beta and Delta each remain responsive to at least one anti-RBD ( 8 , 9 , 21 ).”
From Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa (2021) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · see citing works
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119 · see citing works
SARS-CoV-2 vaccines in development
Krammer, F. (2020) · Nature · doi:10.1038/s41586-020-2798-3 · Cited by 2,098 · see citing works
Self-citationStadlbauer, D., Amanat, F., Chromikova, V., Jiang, K., Strohmeier, S., Arunkumar, G. A., Tan, J., Bhavsar, D., Capuano, C., Roubidoux, E. K., et al. (2020) · Current Protocols in Microbiology · doi:10.1002/cpmc.100 · Cited by 623 · see citing works
Self-citationRepeated cross-sectional sero-monitoring of SARS-CoV-2 in New York City
Stadlbauer, D., Tan, J., Jiang, K.-J., Hernandez, M., Fabre, S., Amanat, F., Teo, C., Arunkumar, G., McMahon, M., Capuano, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2912-6 · Cited by 140 · see citing works
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization
Planas, D., Veyer, D., Baidaliuk, A., Staropoli, I., Guivel-Benhassine, F., Rajah, M. M., Planchais, C., Porrot, F., Robillard, N., Puech, J., et al. (2021) · Nature · doi:10.1038/s41586-021-03777-9 · Cited by 1,992 · see citing works
Increased risk of SARS-CoV-2 reinfection associated with emergence of Omicron in South Africa
Pulliam, J. R. C., van Schalkwyk, C., Govender, N., Gottberg, A. V., Cohen, C., Groome, M. J., Dushoff, J., Mlisana, K., & Moultrie, H. (2021) · doi:10.1101/2021.11.11.21266068 · Cited by 1,037 · see citing works
Menni, C., Klaser, K., May, A., Polidori, L., Capdevila, J., Louca, P., Sudre, C. H., Nguyen, L. H., Drew, D. A., Merino, J., et al. (2021) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(21)00224-3 · Cited by 1,031 · see citing works
Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection
Wang, Z., Muecksch, F., Schaefer-Babajew, D., Finkin, S., Viant, C., Gaebler, C., Hoffmann, H. H., Barnes, C. O., Cipolla, M., Ramos, V., et al. (2021) · Nature · doi:10.1038/s41586-021-03696-9 · Cited by 721 · see citing works
mRNA vaccination boosts cross-variant neutralizing antibodies elicited by SARS-CoV-2 infection
Stamatatos, L., Czartoski, J., Wan, Y.-H., Homad, L. J., Rubin, V., Glantz, H., Neradilek, M., Seydoux, E., Jennewein, M. F., MacCamy, A. J., et al. (2021) · Science · doi:10.1126/science.abg9175 · Cited by 557 · see citing works
Painter, M. M., Mathew, D., Goel, R. R., Apostolidis, S. A., Pattekar, A., Kuthuru, O., Baxter, A. E., Herati, R. S., Oldridge, D. A., Gouma, S., et al. (2021) · Immunity · doi:10.1016/j.immuni.2021.08.001 · Cited by 499 · see citing works
Prior SARS-CoV-2 infection rescues B and T cell responses to variants after first vaccine dose
Reynolds, C. J., Pade, C., Gibbons, J. M., Butler, D. K., Otter, A. D., Menacho, K., Fontana, M., Smit, A., Sackville-West, J. E., Cutino-Moguel, T., et al. (2021) · Science · doi:10.1126/science.abh1282 · Cited by 338 · see citing works
Lustig, Y., Sapir, E., Regev-Yochay, G., Cohen, C., Fluss, R., Olmer, L., Indenbaum, V., Mandelboim, M., Doolman, R., Amit, S., et al. (2021) · The Lancet Respiratory Medicine · doi:10.1016/s2213-2600(21)00220-4 · Cited by 342 · see citing works
Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection
Cromer, D., Juno, J. A., Khoury, D., Reynaldi, A., Wheatley, A. K., Kent, S. J., & Davenport, M. P. (2021) · Nature Reviews Immunology · doi:10.1038/s41577-021-00550-x · Cited by 265 · see citing works
Jones, J. M., Stone, M., Sulaeman, H., Fink, R. V., Dave, H., Levy, M. E., Di Germanio, C., Green, V., Notari, E., Saa, P., et al. (2021) · JAMA · doi:10.1001/jama.2021.15161 · Cited by 201 · see citing works
Kremsner, P., Mann, P., Bosch, J., Fendel, R., Gabor, J. J., Kreidenweiss, A., Kroidl, A., Leroux-Roels, I., Leroux-Roels, G., Schindler, C., et al. (2020) · doi:10.1101/2020.11.09.20228551 · Cited by 199 · see citing works
SARS-CoV-2 antibody response in persons with past natural infection
Anichini, G., Terrosi, C., Gandolfo, C., Gori Savellini, G., Fabrizi, S., Miceli, G. B., & Cusi, M. G. (2021) · New England Journal of Medicine · doi:10.1056/nejmc2103825 · Cited by 141 · see citing works
Mazzoni, A., Di Lauria, N., Maggi, L., Salvati, L., Vanni, A., Capone, M., Lamacchia, G., Mantengoli, E., Spinicci, M., Zammarchi, L., et al. (2021) · Journal of Clinical Investigation · doi:10.1172/jci149150 · Cited by 139 · see citing works
Eyre, D. W., Lumley, S. F., Wei, J., Cox, S., James, T., Justice, A., Jesuthasan, G., O'Donnell, D., Howarth, A., Hatch, S. B., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.05.041 · Cited by 131 · see citing works
- Authors
- Krammer, F., Srivastava, K., Alshammary, H., Amoako, A. A., Awawda, M. H., Beach, K. F., Bermúdez-González, M. C., Bielak, D. A., Carreño, J. M., Chernet, R. L., Eaker, L. Q., Ferreri, E. D., Floda, D. L., Gleason, C. R., Hamburger, J. Z., Jiang, K., Kleiner, G., Jurczyszak, D., Matthews, J. C., Mendez, W. A., Nabeel, I., Mulder, L. C. F., Raskin, A. J., Russo, K. T., Salimbangon, A.-B. T., Saksena, M., Shin, A. S., Singh, G., Sominsky, L. A., Stadlbauer, D., Wajnberg, A., & Simon, V.
- Affiliations
- Icahn School of Medicine at Mount Sinai (US)
- Corresponding author
- Simon, Viviana
- ORCID
- Krammer, Florian
- Alshammary, Hala
- Amoako, Angela A.
- Beach, Katherine F.
- Bermúdez-González, Maria C.
- Carreño, Juan M.
- Chernet, Rachel L.
- Ferreri, Emily D.
- Gleason, Charles R.
- Jiang, Kaijun
- Kleiner, Giulio
- Jurczyszak, Denise
- Nabeel, Ismail
- Mulder, Lubbertus C.F.
- Raskin, Ariel J.
- Saksena, Miti
- Singh, Gagandeep
- Sominsky, Levy A.
- Stadlbauer, Daniel
- Wajnberg, Ania
- Simon, Viviana
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2021-04-08
- Volume
- 384
- Issue
- 14
- Pages
- 1372-1374
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC8008743
- OpenAlex
- W3135210768
- Cited by
- 696
- References
- 5
- Citations by year
- 2026: 9 · 2025: 16 · 2024: 38 · 2023: 86 · 2022: 231 · 2021: 314
- FWCI
- 52.97
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Allergy and Infectious Diseases (75N93019C00051, HHSN272201400008C)
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Infectious Diseases › COVID-19 Clinical Research Studies
- Life Sciences › Immunology and Microbiology › Immunology › Immune responses and vaccinations
- Keywords
- SARS-CoV-2, COVID-19 pandemic, mRNA vaccines, seropositive individuals, prior SARS-CoV-2 infection, antibody response, spike protein antibodies, single-dose vaccination, vaccine efficacy
- MeSH terms
- COVID-19, SARS-CoV-2, COVID-19 Vaccines, Adult, Aged, Antibodies, Viral, Female, Humans, Immunoglobulin G, Male, Middle Aged, Area Under Curve, Immunogenetic Phenomena, Antibodies, Neutralizing, Spike Glycoprotein, Coronavirus
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
